dia-lp-header-logo-only-1024x200-2
Weave_Logo-Horizontal-FullColor_RGB (1)
Parexel_logo-3

 

 Augmentation, Not Automation: How to Get the Best of All Worlds

with People + AI


October 8 | 1:00-2:00 PM ET | On-Demand Post Event

 

Overview

AI workflow solutions are moving into regulatory work faster than most teams can evaluate it. Meanwhile, authoring bottlenecks, drawn-out review cycles, and tight health authority timelines keep piling pressure on teams, and the standard for quality can't move. The real opportunity isn't choosing between AI and human judgment, it's knowing exactly where each does its best work, and where they're strongest combined. Weave and Parexel take on that question together: an AI-native platform built specifically for the regulatory process in drug development, paired with the regulatory expertise and firsthand view of what health authorities expect. Drawing on real deployment experience across organizations of various sizes, they get specific about where AI accelerates the work, where regulatory judgment has to lead, and how the two work best in tandem. Using real examples, they'll show exactly what that looks like in practice.

AI is reshaping the regulatory process in drug development.  Join Weave and Parexel on speed, judgment, and where they meet.

Register Now!

 

Featured Topics:
 

  • Closing authoring bottlenecks without sacrificing scientific or regulatory quality

  • Compressing review cycles while keeping expert judgment at the center of every decision

  • Meeting health authority response timelines under real-world pressure

  • How to discern AI built to solve a problem from AI built to check a box

Speakers:

Daniel Pointing

Director of Business Development and Strategy, Weave

Daniel Pointing

As Associate Director of Business Development at Weave Bio, Daniel works with biotech and pharma teams to improve how regulatory submissions are developed, using AI in practical, trusted ways that support expert judgment. With more than 10 years of experience across clinical trials, data science, strategic partnerships, and business development, he brings a multidisciplinary perspective to complex drug development challenges. His background spans oncology and infectious disease research, biomarker discovery, AI-driven patient stratification, and global partnerships across North America, Europe, and APAC, helping him connect scientific complexity with real-world business and operational needs.

Ryan Zettle
Executive Director,  Regulatory Affairs and AI Innovation, Parexel

RyanZettle PXL 2026-1

As Executive Director of Regulatory Affairs and AI Innovation at Parexel, Ryan leads the identification, assessment, and implementation of AI and automation solutions transforming regulatory submissions and document authoring. With 12+ years of progressive experience spanning the FDA and Parexel, he has overseen complex regulatory submissions across US, EU, and APAC markets while driving digital transformation initiatives that reduce cycle times and enhance accuracy. Currently architecting governance frameworks for innovative AI use in regulated environments, Ryan combines deep regulatory expertise with strategic vision to help unlock AI's potential in critical workflows. 

 

 

 

Register Now